Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Posts Q2 Revenue Growth, Ballooning Net Loss

NEW YORK, July 24 - Ciphergen Biosystems today reported string growth in second-quarter revenue atop increased R&D spending and widened net loss.

 

Revenue for the period ended June 30 surged to $14.3 million from $8.7 million in the year-ago period. Ciphergen attributed the increase to greater sales of its ProteinChip systems and arrays, its automation accessories, and from its BioSepra process proteomics products.

 

R&D spending also saw an increase in the second quarter, to $7 million from $4.7 million in the same period last year.

 

Second-quarter net loss swelled to $15.6 million, or $.56 per share, from $4.7 million, or $.7.3 million per share, year over year. Ciphergen said a contributing factor of the increased loss was $7.3 million in litigation fees as part of a settlement with LumiCyte.

 

As GenomeWeb reported at the end of May, Ciphergen, LumiCyte, and Molecular Analytical Systems settled their lawsuit over a mass-spectrometry technology called SELDI-TOF.

 

Under the terms of the settlement, Ciphergen will pay Molecular Analytical Systems revenue-based royalties of up to $10 million over 10 years. Ciphergen will also issue about 1.25 million shares to LumiCyte and pay the company about $3 million in cash.

 

In return, Ciphergen will gain access to Molecular Analytical's exclusive worldwide patent rights to surface enhanced laser desorption ionization time-of-flight mass spectrometry, or SELDI-TOF-MS.

 

Ciphergen said it had around $28.2 million in cash, cash equivalents, and investments as of June 30.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.